Clinical Trials Directory

Trials / Completed

CompletedNCT02284542

NAPS: Non-awake Versus Awake Placement of Spinal Cord Stimulators

NAPS (Non-awake Versus Awake Placement of Spinal Cord Stimulators) Study for the Evaluation of Awake and Non-awake Methods of SCS Paddle Lead Placement

Status
Completed
Phase
Study type
Observational
Enrollment
34 (actual)
Sponsor
St. Luke's Hospital, Pennsylvania · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The primary objective is to demonstrate the safety and efficacy of a non-awake implantation method (EMG neuromonitoring) of a SCS paddle lead as compared to an awake implantation method (with local anesthesia and patient feedback).This is a post-market, prospective, multicenter, parallel designed, non-randomized, non-blinded, 6-month study. A minimum of 50 patients will be implanted from up to 4 active sites, coordinated by a single lead investigator. Patients who have had a successful SCS trial and are indicated for permanent implantation will be approached to participate in this study prior to permanent implantation. Patients will be recruited and enrolled by physicians at any one of the involved sites. Each Investigator will only use one method (awake or non-awake) according to his/her typical practice. Patients will receive treatment from their enrolling physician.

Conditions

Interventions

TypeNameDescription
PROCEDUREAwakeUpon approximate lead positioning, the patient is brought to a conscious sedated state while maintaining local anesthetic. Stimulation of the spinal cord through the paddle lead is accomplished with an external pulse generator, while communicating with the patient regarding paresthesia coverage of painful regions.
PROCEDURENon-AwakeThe patient is maintained under general anesthesia for the full duration of the implant. Upon approximate lead positioning, bilateral EMG of myotomes overlapping dermatomal regions of pain are monitored. Stimulation is delivered through the lead by an external pulse generator in order to elicit compound muscle action potentials (CMAPs) in the target regions. Lead placement is targeted to have symmetric CMAPs (i.e. physiologic midline) and adequate coverage of the painful regions as described by Falowski et al. (Falowski et al., 2011).

Timeline

Start date
2014-11-01
Primary completion
2017-01-31
Completion
2017-01-31
First posted
2014-11-06
Last updated
2021-10-22

Locations

4 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT02284542. Inclusion in this directory is not an endorsement.